Table 2.

 Prognostic value of common genetic alterations for overall survival (OS) and progression‐free survival (PFS) in gliomas (multivariate analysis)

	PFS			OS
	P‐value	Hazard ratio	95% CI	P‐value	Hazard ratio	95% CI
Grade 2 glioma
IDH mutation	0.4408	0.602	0.1678–2.1535	0.1573	0.329	0.0728–1.5270
1p/19q co‐deletion	0.3591	0.495	0.1083–2.2020	0.7988	1.237	0.2353–6.0194
TP53 mutation	0.2904	2.036	0.5526–7.7157	0.4693	0.537	0.0685–2.6350
Grade 3 glioma
IDH mutation	<0.0001†	0.059	0.0086–0.2395	0.0403†	0.319	0.0985–0.9519
1p/19q co‐deletion	0.0016†	0.055	0.0025–0.3904	0.0170†	0.184	0.0271–0.7567
TP53 mutation	0.4144	0.646	0.2045–1.7994	0.0300†	0.294	0.0786–0.8937
Primary GBM
IDH mutation	0.8456	0.898	0.2575–2.4255	0.8560	0.905	0.2609–2.4203
TP53 mutation	0.1533	0.605	0.2792–1.1944	0.3089	0.705	0.3354–1.3613
Methylated MGMT promoter	0.0031†	0.407	0.2216–0.7375	0.0058†	0.429	0.2324–0.7820

†Significant value. Cox proportional hazard modeling for OS or PFS was applied for the major variable for prognostic factors. CI, confidence interval; GBM, glioblastoma.